Jacob Asset Management of New York’s Apellis Pharmaceuticals APLS Stock Holding History

Jacob Asset Management of New York’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$184K	Buy	4,850 +4,416	+1,018%	+$194K	0.26%	56
2023 Q2	$39.5K	Sell	434 -110	-20%	-$9.49K	0.04%	65
2023 Q1	$35.9K	Sell	544 -3,500	-87%	-$202K	0.04%	64
2022 Q4	$209K	Buy	4,044 +1,385	+52%	+$73.5K	0.25%	55
2022 Q3	$182K	Buy	2,659 +1,005	+61%	+$59.5K	0.2%	60
2022 Q2	$75K	Sell	1,654 -1,645	-50%	-$75K	0.08%	70
2022 Q1	$168K	Sell	3,299 -9,556	-74%	-$422K	0.1%	71
2021 Q4	$608K	Sell	12,855 -3,233	-20%	-$127K	0.27%	59
2021 Q3	$530K	Buy	16,088 +2,888	+22%	+$162K	0.19%	65
2021 Q2	$834K	Buy	13,200 +3,200	+32%	+$165K	0.28%	67
2021 Q1	$429K	Hold	10,000	–	–	0.17%	72
2020 Q4	$572K	Buy	+10,000	New	+$423K	0.43%	45

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jacob Asset Management of New York's APLS Position: Q3 2023 in Review

Jacob Asset Management of New York increased its Apellis Pharmaceuticals (APLS) stake by 1,018% in Q3 2023, buying an estimated $194K and bringing the position to 4,850 shares worth $184K. The position accounts for 0.26% of the portfolio, ranked #56.

Jacob Asset Management of New York first reported a position in APLS in Q4 2020 and has held it in 12 quarters since. The position peaked at $834K in Q2 2021. 256 funds tracked by Wall St. Rank hold APLS as of Q3 2023.

Jacob Asset Management of New York held 4,850 shares of Apellis Pharmaceuticals worth $184K as of Q3 2023.
Jacob Asset Management of New York bought 4,416 Apellis Pharmaceuticals shares in Q3 2023, an estimated $194K.
Apellis Pharmaceuticals made up 0.26% of Jacob Asset Management of New York's portfolio in Q3 2023, its #56 holding.
Jacob Asset Management of New York first reported a position in Apellis Pharmaceuticals in Q4 2020 and has held it in 12 quarters since.
Jacob Asset Management of New York's Apellis Pharmaceuticals position peaked at $834K in Q2 2021.
256 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2023.

Based on Jacob Asset Management of New York's 13F filing for Q3 2023, filed 1 Nov 2023.